



# Citi Pharma Limited

October 02, 2025

The General Manager  
Pakistan Stock Exchange Limited  
Stock Exchange Building  
Stock Exchange Road  
Karachi.

## Financial results for the year ended June 30, 2025

Dear Sir,

We have to inform you that the Board of Directors of the company in their meeting held on Thursday, October 02, 2025 at 12:30 Pm 588 Block Q, Phase 2 Johar Town, Lahore Lahore have Recommended the the following.

- |   |                 |
|---|-----------------|
| 1. Cash Dividend                          | 3.5/SHARE (35%) |
| 2. Bonus Shares                           | Nil             |
| 3. Right Shares                           | Nil             |
| 4. Any other entitlement/corporate action | Nil             |
| 5. Any other Price sensitive information  | Nil             |

Statement of Financial Position, Statement of Profit or loss and Other Comprehensive Income, Statement of Changes in Equity and Statement of Cash flows of the Company for the year ended June 30, 2025, are enclosed as annexures.

The Annual General Meeting (AGM) of the Company will be held on Monday, October 27, 2025 at 12:30 PM at 588 Block Q, Phase 2 Johar Town, Lahore, the head Office of the Company.

The Share Transfer Books of the Company will be closed from October 21, 2025 to October 27, 2025 (both days inclusive). Physical transfers / CDS Transaction IDs received at the Company's Share Registrar, M/s. F.D. Registrar Services (PVT) Ltd. 17th Floor, Salma Trade Tower-A, I.I. Chundrigar Road Karachi, at the close of business on October 20, 2025 will be treated in time to determine voting rights of the shareholders for attending the meeting.

The Annual Financial Statements (Annual Report) of the Company shall be transmitted through PUCARS at least 21 days before holding of AGM.

Yours Sincerely,

Ghulam Dastgeer  
Company Secretary



Cc:

Executive Director/HOD, Offsite-II, Department

Supervision Division, Securities & Exchange Commission of Pakistan



588 - Q, Johar Town, Lahore - Pakistan



3KM. Head Balloki Road, Phool Nagar, District Kasur - Pakistan



Head Office : +92. 42. 35316587 - 90 | Factory: +92. 49. 4510189, +92. 49. 4513392



www.citipharma.com.pk

CITI PHARMA LIMITED  
STATEMENT OF PROFIT OR LOSS  
FOR THE YEAR ENDED JUNE 30, 2025

	Note	JUNE 30, 2025 Rupees	JUNE 30, 2024 Rupees
Sales - net	23	13,153,521,857	12,409,238,742
Cost of sales	24	(11,135,913,539)	(10,823,043,626)
Gross profit		2,017,608,317	1,586,195,116
Administrative and general expenses	25	222,111,434	204,140,660
Marketing and distribution expenses	26	191,248,622	176,413,202
		(413,360,056)	(380,553,862)
Operating Profit		1,604,248,261	1,205,641,254
Financial Charges	27	(329,672,942)	(299,906,390)
		1,274,575,319	905,734,864
Other income	28	198,270,120	489,667,362
		1,472,845,439	1,395,402,226
Other Expenses	29	(118,335,610)	(114,200,518)
Profit before income taxes and final taxes		1,354,509,829	1,281,201,708
Taxation - Final taxes	30	-	(3,296,190)
Profit before income tax		1,354,509,829	1,277,905,518
Taxation - Income tax	30	(462,470,896)	(444,441,671)
Profit after income tax		892,038,933	833,463,847
Earnings per share- basic and dilutive (Rupees)	31	3.90	3.65



CITI PHARMA LIMITED  
STATEMENT OF FINANCIAL POSITION  
AS AT JUNE 30, 2025

	Note	JUNE 30, 2025 Rupees	JUNE 30, 2024 Rupees
<b>EQUITY AND LIABILITIES</b>			
<b>SHARE CAPITAL AND RESERVES</b>			
Authorised Capital:			
300,000,000 Ordinary shares of Rs. 10/- each		3,000,000,000	3,000,000,000
Share Capital			
Issued, subscribed and paid up capital	4	2,284,612,000	2,284,612,000
Capital Reserves			
Share premium	5	1,391,532,000	1,391,532,000
Revaluation Surplus	6	5,384,617,300	309,294,525
		6,776,149,300	1,700,826,525
Revenue Reserve			
Unappropriated Profit		1,806,817,381	1,647,690,917
		10,867,578,681	5,633,129,442
<b>NON-CURRENT LIABILITIES</b>			
Long Term Financing - Secured	7	-	-
Deferred Liabilities	8	261,763,862	206,710,153
Deferred Grant	9	-	-
Lease Liabilities	10	64,864,123	-
		266,627,986	206,710,153
<b>CURRENT LIABILITIES</b>			
Trade and other payables	11	3,858,531,251	3,600,331,259
Due to Related Parties	12	5,686,383	43,420,000
Short Term Borrowings-Secured	13	2,863,211,696	1,393,095,588
Current portion of long term liabilities	14	15,802,536	18,865,031
Unclaimed Dividend		4,045,868	1,389,901
Accrued Mark Up		38,268,523	71,473,816
Provision for taxation		519,677,557	470,831,450
		7,305,243,814	5,599,407,045
	15		
		18,439,450,481	11,439,246,639
<b>ASSETS</b>			
<b>NON-CURRENT ASSETS</b>			
Property, plant and equipment	16	8,487,898,852	3,519,694,352
Long term Security Deposits		25,643,117	20,217,776
Long Term Advance	17	254,540,900	254,540,900
		8,967,882,869	3,804,453,028
<b>CURRENT ASSETS</b>			
Stock in Trade	18	3,929,791,530	3,203,374,300
Trade Debts - Unsecured	19	3,078,215,648	2,196,877,403
Advances, Deposits, prepayments & other Receivables	20	903,706,936	840,351,401
Short Term Investments	21	956,388,685	1,306,290,577
Cash and Bank Balances	22	603,552,814	87,899,930
		9,471,567,612	7,634,793,612
		18,439,450,481	11,439,246,640



CITI PHARMA LIMITED  
STATEMENT OF CHANGES IN EQUITY  
FOR THE YEAR ENDED JUNE 30, 2025

PARTICULARS	SHARE CAPITAL	CAPITAL RESERVES		REVENUE RESERVES	TOTAL
		REVALUATION SURPLUS	SHARE PREMIUM	UN-APPROPRIATED PROFIT	
		-----Rupees-----			
Balance as at June 30, 2023	2,284,612,000	309,294,525	1,391,532,000	1,787,436,786	5,772,675,311
Final Dividend Paid for the year ended June 2023 @ 25%	-	-	-	(571,153,000)	(571,153,000)
Profit for the year	-	-	-	833,463,647	833,463,647
Other Comprehensive loss (Net of tax)	-	-	-	(2,254,716)	(2,254,716)
Balance as at June 30, 2024	2,284,612,000	309,294,525	1,391,532,000	1,667,696,917	5,633,129,442
Final Dividend Paid for the year ended June 2024 @ 32.5%	-	-	-	(742,498,902)	(742,498,902)
Surplus on revaluation of property, plant & equipment	-	5,075,322,775	-	-	5,075,322,775
Profit for the year	-	-	-	882,036,933	882,036,933
Other Comprehensive Income (Net of tax)	-	-	-	9,586,433	9,586,433
Balance as at June 30, 2025	2,284,612,000	5,384,617,300	1,391,532,000	1,806,817,381	10,867,578,681

181



CITI PHARMA LIMITED  
STATEMENT OF CASH FLOWS  
FOR THE YEAR ENDED JUNE 30, 2025

	JUNE 30, 2025 Rupees	JUNE 30, 2024 Rupees
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>		
Profit before income taxes and final taxes	1,254,509,829	1,281,201,708
<b>Adjustments For Non-Cash Items And Other Line Items</b>		
Depreciation	368,085,212	338,220,523
Gratuity Expense	33,273,898	29,839,062
Allowance for expected credit loss	2,200,936	4,778,739
Unrealized Exchange Loss	-	(9,043,317)
Amortization of Deferred Grant	-	-
Unrealized Loss on Investment in Shares	2,790,037	-
Un-Realized gain on Investment in shares	-	(29,381,385)
Accrued Interest	(1,969,600)	(7,049,678)
Financial Charges	329,672,942	299,906,390
Worker's Profit Participation Fund	72,611,424	68,780,302
Worker's Welfare Fund	27,051,315	25,624,034
	631,715,864	527,572,877
Profit before working capital changes	1,986,225,693	1,808,774,585
Effect of working capital changes:		
Advances, Deposits And Prepayments	78,125,799	(146,787,882)
Trade Debts	(885,740,076)	(282,487,404)
Stock In Trade	(726,327,230)	(594,390,728)
Trade and other payables	227,317,586	1,350,957,848
	(1,304,632,951)	395,091,737
Financial Charges Paid	(356,032,457)	(289,990,951)
Income Tax Paid	(573,995,150)	(461,131,101)
Gratuity Paid	(2,697,050)	(1,055,955)
Worker's Profit Participation Fund paid	(68,780,302)	(54,091,160)
	(1,602,304,959)	(806,269,167)
Net cash flow from operating activities	<b>A</b> (326,709,217)	1,337,597,155
<b>CASH FLOW FROM INVESTING ACTIVITIES</b>		
Purchase of Property And Equipment	(86,123,857)	(326,942,364)
Capital Work In Progress	(63,940,621)	(241,253,833)
Long Term Security Deposits	(5,225,341)	3,427,788
Short Term Investments	42,307,825	52,829,344
Net cash flow from investing activities	<b>B</b> (112,981,993)	(511,938,645)
<b>CASH FLOW FROM FINANCING ACTIVITIES</b>		
Long-term loans repaid	(12,059,000)	(51,558,110)
Current portion of deferred grant	(582,498)	-
Liability Against Assets Subject To Finance Lease	(32,294,240)	(4,609,309)
Due to Related Parties	(37,733,617)	(254,060,434)
Dividend Paid	(739,822,935)	(571,153,000)
Short Term Borrowings	1,476,316,398	(77,475,888)
Net Cash Flow From financing Activities	<b>C</b> 646,823,823	(958,856,741)
Net Increase/ (Decrease) In Cash And Cash Equivalents	<b>A+B+C</b> 213,138,613	(133,198,431)
Cash And Cash Equivalents At Beginning of the Year	1,278,333,631	1,411,532,062
Cash And Cash Equivalents At End Of The Year	1,491,472,244	1,278,333,631
Cash and cash equivalents comprise of:		
Cash in hand	866,166	26,505
Cash at bank	602,708,667	87,873,425
Short Term Investments	887,919,430	1,190,433,701
	1,496,472,244	1,278,333,631

